ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CABA Cabaletta Bio Inc

13.34
-0.63 (-4.51%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,178,220
Bid Price 13.00
Ask Price 13.36
News -
Day High 14.28

Low
7.69

52 Week Range

High
26.35

Day Low 13.08
Company Name Stock Ticker Symbol Market Type
Cabaletta Bio Inc CABA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.63 -4.51% 13.34 20:00:00
Open Price Low Price High Price Close Price Prev Close
13.90 13.08 14.28 13.34 13.97
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,111 1,178,220 $ 13.60 $ 16,021,597 - 7.69 - 26.35
Last Trade Time Type Quantity Stock Price Currency
18:59:45 10 $ 13.36 USD

Cabaletta Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
571.61M 42.85M - 0 -67.68M -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cabaletta Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CABA Message Board. Create One! See More Posts on CABA Message Board See More Message Board Posts

Historical CABA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.7418.4413.0815.62986,559-4.40-24.80%
1 Month16.9119.0413.0816.801,009,785-3.57-21.11%
3 Months22.3526.3513.0820.05971,400-9.01-40.31%
6 Months14.0026.359.5518.611,083,618-0.66-4.71%
1 Year8.4326.357.6916.88835,5564.9158.24%
3 Years10.6626.350.599.54655,5542.6825.14%
5 Years9.4526.350.599.67471,8183.8941.16%

Cabaletta Bio Description

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.

Your Recent History

Delayed Upgrade Clock